Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | IDH2 | P48735 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16423045 | 0.84 | LMNA (0.32) | LMNAMAPTPOLBKMT2AIDH1 | |
| SCHEMBL2187990 | 0.84 | — | — | |
| SCHEMBL5514256 | 0.81 | — | — | |
| SCHEMBL5514252 | 0.80 | LMNA (0.30) | LMNA | |
| SCHEMBL2187271 | 0.79 | LMNA (0.42) | LMNAMAPTPOLBKMT2AMEN1 | |
| SCHEMBL2185532 | 0.79 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22111912 | 0.79 | LMNA (0.39) | LMNAMAPTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10716962 | 0.79 | POLB (0.39) | LMNAMAPTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL950089 | 0.79 | LMNA (0.45) | LMNAMAPTPOLBKMT2AMEN1 | |
| SCHEMBL14384098 | 0.79 | CCR1 (0.40) | LMNAMAPTPOLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110770214-B | Heterocyclic P2X7 antagonists | 布雷耶疗法有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | BREYE THERAPEUTICS APS (DK) | 2023-04-11 | — | — | US | disclosed |
| EP-3619200-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | AXXAM S.p.A. (IT) | 2020-03-11 | — | — | EP | disclosed |
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2020-02-20 | — | — | US | disclosed |
| CN-110770214-A | Heterocyclic P2X7 antagonists | 阿克萨姆股份公司 | 2020-02-07 | — | — | CN | disclosed |
| WO-2018202694-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | AXXAM S.P.A. (IT) | 2018-11-08 | — | — | WO | disclosed |
| EP-3398941-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | AXXAM S.p.A. (IT) | 2018-11-07 | — | — | EP | disclosed |
| EP-2832728-B1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL IND LTD (JP) | 2018-09-05 | — | — | EP | disclosed |
| CN-104203928-B | Triazineon compounds and T-shaped calcium channel blocker | 日产化学工业株式会社 | 2017-06-06 | — | — | CN | disclosed |
| US-20160340322-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| US-7541374-B2 | Malononitrile compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7541374-B2 | Malononitrile compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7541374-B2 | Malononitrile compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-02 | — | — | US | disclosed |
| CN-100457108-C | Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor | MERCK & CO INC (US) | 2009-02-04 | — | — | CN | disclosed |
| US-20070117854-A1 | Malononitrile compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20070117854-A1 | Malononitrile compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20070117854-A1 | Malononitrile compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| CN-1910147-A | Malononitrile compounds and their use | SUMITOMO CHEMICAL CO (JP) | 2007-02-07 | — | — | CN | disclosed |
| EP-1710234-A1 | MALONONITRILE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2006-10-11 | — | — | EP | disclosed |
| CN-1845674-A | Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor | MERCK & CO INC (US) | 2006-10-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | P2RY1, P2RX1, P2RX3 | LMNA 2079/4885MAPT 4279/4885SLC6A2 608/4885 |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | P2RY1, P2RX1, P2RX3 | LMNA 2079/4885MAPT 4279/4885SLC6A2 608/4885 |
| US-20160340322-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1E, CACNA1I, CACNA1G | LMNA 1847/4885MAPT 1295/4885SLC6A2 503/4885 |
| US-20070117854-A1 | Malononitrile compounds and use thereof | ME1, DDT, CYP51A1 | LMNA 3587/4885MAPT 2498/4885SLC6A2 3536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.